• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Advertisement

New Delhi, March 7 Ranbaxy Laboratories Ltd on Wednesday said its Romanian company Terapia Ranbaxy has received Market Authorisations (MAs) for 20 new products to be launched in the coming months.

In June 2006, Ranbaxy had announced that Ranbaxy Netherlands BV had completed the acquisition process of 96.7 per cent of the top Romanian generics firm Terapia SA. The combined operations of Terapia Ranbaxy established the largest Romanian generics firm.

"The list of MAs granted by the National Agency of Medicine refers to products from different therapeutic areas mainly from the cardiovascular, antibiotics or CNS segments. These are either new molecules on the market like Citaloran and modern formulations like Lamotiran - oral dispersible tablets, Pravator, Quinaran, Terbinaran among others," Terapia Ranbaxy CEO Mr Dragos Damian said in a statement. He added that the new launches reinforced the company's promise to bring value-added niche products at affordable prices to the Romanian pharmaceutical market.

With the commercial department structured in business units, Terapia Ranbaxy has a 1,200 strong workforce, of which 350 forms the largest professional field force in the Romanian pharmaceutical market, said the statement.

More Stories on : Regulatory Bodies & Rulings | New Products & Services | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Abbott India stock stays flat despite buyback offer

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line